Jaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%

Reuters04-02

Jaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%

Jaguar Health unit Napo Pharmaceuticals highlighted ongoing investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure tied to microvillus inclusion disease and short bowel syndrome.
Initial study update was presented at April 2025 Elite Ped-GI Congress, with additional results presented at November 2025 NASPGHAN annual meeting.
Company cited study outcomes showing reduced reliance on parenteral support, positioning crofelemer as potential disease-modifying therapy in microvillus inclusion disease.
Long-term safety and efficacy update is slated for potential presentation at ESPGHAN annual meeting in June 2026, following abstract submission.
Jaguar pegged global market for short bowel syndrome, including intestinal failure, at about $8 billion by 2033.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on April 02, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624501763?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624501763","market":"us","top_or_hot":-1,"title":"Jaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Jaguar Health unit Napo Pharmaceuticals highlighted ongoing investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure tied to microvillus inclusion disease and short bowel syndrome.\n        </li>\n<li>\n          Initial study update was presented at April 2025 Elite Ped-GI Congress, with additional results presented at November 2025 NASPGHAN annual meeting.\n        </li>\n<li>\n          Company cited study outcomes showing reduced reliance on parenteral support, positioning crofelemer as potential disease-modifying therapy in microvillus inclusion disease.\n        </li>\n<li>\n          Long-term safety and efficacy update is slated for potential presentation at ESPGHAN annual meeting in June 2026, following abstract submission.\n        </li>\n<li>\n          Jaguar pegged global market for short bowel syndrome, including intestinal failure, at about $8 billion by 2033.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on April 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-02 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Jaguar Health unit Napo Pharmaceuticals highlighted ongoing investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure tied to microvillus inclusion disease and short bowel syndrome.\n        </li>\n<li>\n          Initial study update was presented at April 2025 Elite Ped-GI Congress, with additional results presented at November 2025 NASPGHAN annual meeting.\n        </li>\n<li>\n          Company cited study outcomes showing reduced reliance on parenteral support, positioning crofelemer as potential disease-modifying therapy in microvillus inclusion disease.\n        </li>\n<li>\n          Long-term safety and efficacy update is slated for potential presentation at ESPGHAN annual meeting in June 2026, following abstract submission.\n        </li>\n<li>\n          Jaguar pegged global market for short bowel syndrome, including intestinal failure, at about $8 billion by 2033.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on April 02, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAGX","symbol_name":"Jaguar Animal Health, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL8RRXKc:1","article_id":"2624501763","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624501763","pubTimestamp":1775135198,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jaguar Health unit Napo Pharmaceuticals highlighted ongoing investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure tied to microvillus inclusion disease and short bowel syndrome.Initial study update was presented at April 2025 Elite Ped-GI Congress, with additional results presented at November 2025 NASPGHAN annual meeting.Company cited study outcomes showing reduced reliance on parenteral support, positioning crofelemer as potential disease-modifying therapy in microvillus inclusion disease.Long-term safety and efficacy update is slated for potential presentation at ESPGHAN annual meeting in June 2026, following abstract submission.Jaguar pegged global market for short bowel syndrome, including intestinal failure, at about $8 billion by 2033.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc.","BK4007":"制药"},"translate_title":"Jaguar Health表示crofelemer研究将儿科肠衰竭胃肠外支持削减12%-37%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"Jaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%\n    \n\n\n          Jaguar Health unit Napo Pharmaceuticals highlighted ongoing investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure tied to microvillus inclusion disease and short bowel syndrome.\n        \n\n          Initial study update was presented at April 2025 Elite Ped-GI Congress, with additional results presented at November 2025 NASPGHAN annual meeting.\n        \n\n          Company cited study outcomes showing reduced reliance on parenteral support, positioning crofelemer as potential disease-modifying therapy in microvillus inclusion disease.\n        \n\n          Long-term safety and efficacy update is slated for potential presentation at ESPGHAN annual meeting in June 2026, following abstract submission.\n        \n\n          Jaguar pegged global market for short bowel syndrome, including intestinal failure, at about $8 billion by 2033.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on April 02, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624501763","isCrawlerRequest":true}